Login
Companies $BIAF
$1.98 -$0.02 (1.0%) After hours
bioAffinity Technologies, Inc. logo

bioAffinity Technologies, Inc.

bioaffinitytech.com

What Do They Do?

Performs laboratory tests for physicians, including CyPath Lung, a noninvasive test that helps assess patients for early-stage lung cancer.

How Do They Make Money?

The lab brings in fees for patient tests when results are reported, and for histology and medical-director services when those services are performed.

revenue
SegmentShareRevenue
Health Care, Patient Service
Sold outright

81%
Histology Service Fees
Sold outright

18%
Medical Director Fees
Sold outright
1.1%
Department of Defense Observational Studies
<0.1%
Other Revenues
0.1%
FY2022: 100%

Who Are Their Customers?

Physicians order CyPath Lung for patients being evaluated for lung cancer; PPLS offers the test to physicians and operates a commercial pathology laboratory.

Do Revenues Turn Into Profits?

No. It lost $14.9M in FY2025.

Operating income, FY2025
−172% of revenue
▼ −18% (Loss) vs FY2024 (−$9M, −96%)
Net income, FY2025
−242% of revenue
▼ −65% (Loss) vs FY2024 (−$9M, −97%)
Free cash flow, FY2025
−152% of revenue
▼ −28% (Loss) vs FY2024 (−$7.3M, −78%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −26%
vs $1.4M in Q3 FY2025
Net income
▼ −4% (Loss)
vs −$5.1M in Q3 FY2025
Health Care, Patient Service share of revenue vs 81.1% in Q3 FY2025
  • Sep 8, 2026 Nasdaq confirmed the company regained listing compliance Nasdaq cancelled the scheduled hearing and confirmed the company’s securities will continue to trade on the Nasdaq Capital Market.
  • Aug 18, 2026 AvMEDICAL will distribute CyPath Lung to federal healthcare agencies Its sales team will promote the test to federal customers, including VA medical centers.

Shrinking. Revenue fell 11% in 3 years, from $6.9M in FY2022 to $6.2M in FY2025, about 4% a year.

Ownership of the pathology lab The earlier report described Precision Pathology as developing and performing CyPath Lung under a joint agreement; the latest report says bioAffinity owns and operates the commercial laboratory.

A more focused cancer-treatment effort The earlier report described broader cancer-therapy research; the latest report describes continued research toward topical treatment for squamous cell skin cancer.

Revenue over time
Health Care, Patient Service Histology Service Fees Medical Director Fees Department of Defense Observational Studies Other Revenues
$10M$5M$0

Who Do They Compete With?

Competes with LungLife AI, Biodesix, and Veracyte

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support